Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-01 vs Herceptin with Chemotherapy in HER2+ Early Breast Cancer
NCT03989037Phase 3Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jun 2019
- Primary completion
- Apr 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SIBP-01 in breast cancer (2 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoint: Total Pathologic Complete Response at Cycle 6. Started Jun 2019; status: completed.
02
Drugs
SIBP-01
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03989037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989037.